Streetbeat News

LQDA

Liquidia Corporation

https://www.liquidia.com

Industry

Biotechnology

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Open

10.12

Mkt cap

819M

Volume

943K

High

10.13

P/E Ratio

-6.23

52-wk high

16.99

Low

9.79

Div yield

N/A

52-wk low

6.19

Liquidia Corporation's Yutrepia, a competitor to United Therapeutics' Tyvaso, is expected to enter the market in 2025. Despite financial challenges and competition, Liquidia's low valuation and upcoming product launches make it an attractive investment. Legal battles with United Therapeutics are nearing resolution, potentially allowing Yutrepia's commercial launch by mid-2025.

Portfolio Pulse from

November 15, 2024 | 3:30 pm

Liquidia Corporation held its Q3 2024 earnings call, discussing financial results and corporate updates. Key executives participated, and analysts from various financial institutions attended.

Portfolio Pulse from

November 13, 2024 | 8:00 pm

Liquidia Technologies, Inc. (LQDA) reported a Q3 loss of $0.37 per share, matching the Zacks Consensus Estimate, but showed an improvement in revenue compared to expectations.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

Liquidia Corporation reported its Q3 2024 financial results, highlighting a tentative FDA approval for YUTREPIA™ and a Supreme Court victory regarding patent disputes. The company also raised $100 million in capital.

Portfolio Pulse from

November 13, 2024 | 11:45 am

Pomerantz Law Firm is investigating claims on behalf of investors of Liquidia Corporation (NASDAQ:LQDA). Investors are encouraged to contact the firm for more information.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

Scotiabank has initiated coverage on Liquidia with a Sector Outperform rating and set a price target of $30.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 2:22 pm

Liquidia Corp shares rose after the U.S. Supreme Court declined to review rulings, confirming that Liquidia does not infringe on United Therapeutics' patents.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 2:29 pm

On Monday, several US-listed stocks saw significant gains despite a general market downturn. Pfizer's shares rose 4% after Starboard Value acquired a $1 billion stake. Scholar Rock Holding Corp's shares surged 291% following positive clinical trial results. Duckhorn Portfolio's shares climbed 101.3% after reporting strong financial results and announcing an acquisition by Butterfly Equity. Arcadium Lithium gained 40.1% after a potential acquisition approach by Rio Tinto. Vista Outdoor's shares increased 9.8% following a definitive agreement to sell Revelyst.

Portfolio Pulse from Avi Kapoor

October 07, 2024 | 2:08 pm

The U.S. Supreme Court has declined to review rulings that invalidate United Therapeutics' patent, confirming that Liquidia does not infringe any valid claims of the patents originally asserted by United Therapeutics. This decision is final and not subject to further appeal.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 2:03 pm

Liquidia (NASDAQ:LQDA) has received diverse ratings from 14 analysts, with most being bullish. The average 12-month price target is $26.36, slightly down from previous estimates. Liquidia faces financial challenges, including a decline in revenue and low profitability metrics.

Portfolio Pulse from Benzinga Insights

October 03, 2024 | 5:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.